Amgen, Arrowhead team up on gene-therapies for heart disease

(Reuters) – Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *